12-132659414-C-T

Variant summary

Our verdict is Benign. Variant got -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1

The NM_006231.4(POLE):​c.3156G>A​(p.Thr1052=) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.464 in 1,613,846 control chromosomes in the GnomAD database, including 179,148 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.54 ( 23133 hom., cov: 33)
Exomes 𝑓: 0.46 ( 156015 hom. )

Consequence

POLE
NM_006231.4 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:13

Conservation

PhyloP100: -1.20
Variant links:
Genes affected
POLE (HGNC:9177): (DNA polymerase epsilon, catalytic subunit) This gene encodes the catalytic subunit of DNA polymerase epsilon. The enzyme is involved in DNA repair and chromosomal DNA replication. Mutations in this gene have been associated with colorectal cancer 12 and facial dysmorphism, immunodeficiency, livedo, and short stature. [provided by RefSeq, Sep 2013]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.61).
BP6
Variant 12-132659414-C-T is Benign according to our data. Variant chr12-132659414-C-T is described in ClinVar as [Benign]. Clinvar id is 380212.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr12-132659414-C-T is described in Lovd as [Benign].
BP7
Synonymous conserved (PhyloP=-1.2 with no splicing effect.
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.709 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
POLENM_006231.4 linkuse as main transcriptc.3156G>A p.Thr1052= synonymous_variant 26/49 ENST00000320574.10 NP_006222.2

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
POLEENST00000320574.10 linkuse as main transcriptc.3156G>A p.Thr1052= synonymous_variant 26/491 NM_006231.4 ENSP00000322570 P1

Frequencies

GnomAD3 genomes
AF:
0.535
AC:
81396
AN:
152042
Hom.:
23086
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.715
Gnomad AMI
AF:
0.324
Gnomad AMR
AF:
0.555
Gnomad ASJ
AF:
0.383
Gnomad EAS
AF:
0.701
Gnomad SAS
AF:
0.558
Gnomad FIN
AF:
0.433
Gnomad MID
AF:
0.500
Gnomad NFE
AF:
0.434
Gnomad OTH
AF:
0.528
GnomAD3 exomes
AF:
0.503
AC:
126545
AN:
251400
Hom.:
33325
AF XY:
0.496
AC XY:
67383
AN XY:
135884
show subpopulations
Gnomad AFR exome
AF:
0.716
Gnomad AMR exome
AF:
0.578
Gnomad ASJ exome
AF:
0.390
Gnomad EAS exome
AF:
0.705
Gnomad SAS exome
AF:
0.548
Gnomad FIN exome
AF:
0.430
Gnomad NFE exome
AF:
0.431
Gnomad OTH exome
AF:
0.476
GnomAD4 exome
AF:
0.457
AC:
667281
AN:
1461686
Hom.:
156015
Cov.:
47
AF XY:
0.459
AC XY:
333403
AN XY:
727144
show subpopulations
Gnomad4 AFR exome
AF:
0.716
Gnomad4 AMR exome
AF:
0.572
Gnomad4 ASJ exome
AF:
0.390
Gnomad4 EAS exome
AF:
0.697
Gnomad4 SAS exome
AF:
0.546
Gnomad4 FIN exome
AF:
0.427
Gnomad4 NFE exome
AF:
0.430
Gnomad4 OTH exome
AF:
0.471
GnomAD4 genome
AF:
0.536
AC:
81493
AN:
152160
Hom.:
23133
Cov.:
33
AF XY:
0.537
AC XY:
39967
AN XY:
74386
show subpopulations
Gnomad4 AFR
AF:
0.715
Gnomad4 AMR
AF:
0.555
Gnomad4 ASJ
AF:
0.383
Gnomad4 EAS
AF:
0.701
Gnomad4 SAS
AF:
0.558
Gnomad4 FIN
AF:
0.433
Gnomad4 NFE
AF:
0.434
Gnomad4 OTH
AF:
0.531
Alfa
AF:
0.456
Hom.:
20978
Bravo
AF:
0.551
Asia WGS
AF:
0.590
AC:
2050
AN:
3478
EpiCase
AF:
0.433
EpiControl
AF:
0.430

ClinVar

Significance: Benign
Submissions summary: Benign:13
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:5
Benign, criteria provided, single submitterclinical testingGeneDxOct 30, 2015This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -
Benign, no assertion criteria providedclinical testingClinical Genetics, Academic Medical Center-- -
Benign, criteria provided, single submitterclinical testingLaboratory for Molecular Medicine, Mass General Brigham Personalized MedicineMar 29, 2016Disclaimer: This variant has not undergone full assessment. The following are pr eliminary notes: Frequency -
Benign, criteria provided, single submitterclinical testingPreventionGenetics, part of Exact SciencesOct 17, 2016- -
Benign, no assertion criteria providedclinical testingJoint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+-- -
not provided Benign:4
Benign, criteria provided, single submitternot providedBreakthrough Genomics, Breakthrough Genomics-- -
Benign, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpAug 17, 2016Variant summary: The POLE c.3156G>A (p.Thr1052Thr) variant involves the alteration of a conserved nucleotide, resulting in a synonymous change. One in silico tool predicts a damaging outcome for this variant. 5/5 splice prediction tools predict no significant impact on normal splicing. ESE finder predicts that this variant may affect ESE sites. However, these predictions have yet to be confirmed by functional studies. This variant was found in 9827/18014 control chromosomes at a frequency of 0.5455202 (with numerous hozomygotes occurrence), which significantly exceeds the estimated maximal expected allele frequency of a pathogenic POLE variant (0.0000142), suggesting this variant is likely a benign polymorphism. This variant has been reported in patients and classified by authors as polymorphism. Taken together, this variant is classified as benign. -
Benign, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpFeb 01, 2024- -
Benign, criteria provided, single submitterclinical testingARUP Laboratories, Molecular Genetics and Genomics, ARUP LaboratoriesNov 30, 2023- -
Intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, genital anomalies, and immunodeficiency Benign:1
Benign, criteria provided, single submitterclinical testingGenome-Nilou LabOct 25, 2021- -
Colorectal cancer, susceptibility to, 12 Benign:1
Benign, criteria provided, single submitterclinical testingKCCC/NGS Laboratory, Kuwait Cancer Control CenterJul 07, 2023- -
Hereditary cancer-predisposing syndrome Benign:1
Benign, criteria provided, single submitterclinical testingAmbry GeneticsMay 20, 2015This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Facial dysmorphism-immunodeficiency-livedo-short stature syndrome Benign:1
Benign, criteria provided, single submitterclinical testingGenome-Nilou LabOct 25, 2021- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.61
CADD
Benign
1.9
DANN
Benign
0.50
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs5744857; hg19: chr12-133236000; COSMIC: COSV105207436; API